RS51687B - Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain - Google Patents

Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Info

Publication number
RS51687B
RS51687B RS20110223A RSP20110223A RS51687B RS 51687 B RS51687 B RS 51687B RS 20110223 A RS20110223 A RS 20110223A RS P20110223 A RSP20110223 A RS P20110223A RS 51687 B RS51687 B RS 51687B
Authority
RS
Serbia
Prior art keywords
phenyl
methylphenylsulfanyl
piperidine
treatment
neuropathic pain
Prior art date
Application number
RS20110223A
Other languages
Serbian (sr)
Inventor
Benny Bang-Andersen
André FALDT
Tine Bryan STENSBÖL
Silke Miller
Heidi Lopez De Diego
Original Assignee
H. Lundbeck A/S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S. filed Critical H. Lundbeck A/S.
Publication of RS51687B publication Critical patent/RS51687B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Jedinjenje koje je 4-[2-(4-metilfenil-sulfanil)fenil]piperidinHBr adiciona so u kristalnom obliku.Prijava sadrži još 14 patentnih zahteva.A compound which is a 4- [2- (4-methylphenyl-sulfanyl) phenyl] piperidineHBr addition salt in crystalline form. The application contains 14 more claims.

RS20110223A 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain RS51687B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80500906P 2006-06-16 2006-06-16
DKPA200600816 2006-06-16
DKPA200700423 2007-03-20

Publications (1)

Publication Number Publication Date
RS51687B true RS51687B (en) 2011-10-31

Family

ID=39722478

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20110223A RS51687B (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Country Status (15)

Country Link
JP (1) JP2014098017A (en)
KR (1) KR101472595B1 (en)
AR (1) AR061480A1 (en)
AT (1) ATE508115T1 (en)
BR (1) BRPI0712758A2 (en)
CA (1) CA2784304A1 (en)
DE (1) DE602007014372D1 (en)
DK (1) DK2044020T3 (en)
MY (1) MY150698A (en)
NZ (1) NZ572856A (en)
PT (1) PT2044020E (en)
RS (1) RS51687B (en)
SI (1) SI2044020T1 (en)
TN (1) TNSN08461A1 (en)
TW (1) TWI444365B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101972931B1 (en) 2017-10-19 2019-04-26 재단법인대구경북과학기술원 Balloon type ecog measuring device and its manufacturing method
CN116930385B (en) * 2023-08-08 2024-02-20 北京爱思益普生物科技股份有限公司 Method for measuring concentration of compound in high-salt-concentration preparation
CN117305360A (en) * 2023-09-15 2023-12-29 江南大学 Mammalian cell nucleus transfection liquid, preparation method thereof and application thereof in cell nucleus delivery

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (en) * 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
PL2044020T3 (en) * 2006-06-16 2011-09-30 H Lundbeck As Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Also Published As

Publication number Publication date
KR101472595B1 (en) 2014-12-15
TNSN08461A1 (en) 2010-04-14
TWI444365B (en) 2014-07-11
CA2784304A1 (en) 2007-12-21
AR061480A1 (en) 2008-08-27
MY150698A (en) 2014-02-28
ATE508115T1 (en) 2011-05-15
NZ572856A (en) 2012-02-24
TW200817329A (en) 2008-04-16
SI2044020T1 (en) 2011-06-30
PT2044020E (en) 2011-05-12
DK2044020T3 (en) 2011-08-15
KR20090018630A (en) 2009-02-20
BRPI0712758A2 (en) 2012-09-25
DE602007014372D1 (en) 2011-06-16
JP2014098017A (en) 2014-05-29

Similar Documents

Publication Publication Date Title
NO20090250L (en) Crystalline forms of 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
NZ592543A (en) 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
CL2007002930A1 (en) A COMPOUND 4- [4 - ({[4-CHLORINE-3- (TRIFLUOROMETIL) PHENYL] CARBAMOIL} AMINO) -3-FLUOROFENOXI] -N-METHYLPIRIDIN-2-CARBONXAMIDE MONOHIDRATADO; PREPARATION PROCESS; COMPOSITION AND PHARMACEUTICAL COMBINATION; AND USE FOR THE TREATMENT OF HYPERPROLIFERATI DISORDERS
CY1112345T1 (en) Polymorphic Form of 4- [3- (4-Cyclopropanecarbonyl-Piperazine-1-Carbonyl) -4-Fluoro-Benzyl] -2H-Phthalazin-1-One
DK2044043T4 (en) 1- [2- (2,4-DIMETHYLPHENYL SULFANYL) -PHENYL] PIPERAZINE HYDROBROMID AS A COMPOUND WITH COMBINED SEROTONING INSULATION, 5-HT3 AND 5-HT1A ACTIVITY FOR TREATMENT OF KOGN
WO2008113360A3 (en) 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression
SMAP200900055A (en) Chinazolines for the inhibition of pdk1
SMAP200800059A (en) Chinazolines for the inhibition of pdk1
NZ592224A (en) Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
EA201000545A1 (en) COMPOSITION OF CYBENTENTAN, CONTAINING MANNITE AND / OR MICROCRYSTAL PULSIS
ECSP10010145A (en) USE OF 3,11B-CIS-DIHIDROTETRABENAZINE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND SELF-IMMUNE HONEY MIELITIS
RS51687B (en) Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
MX2010012421A (en) 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethyl amino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinam ide as nk1 receptor antagonists.
BRPI0816221A2 (en) Crystalline Form 1 of 2 - ((r) -2-methylpyrrolidin-2-ol) -1h-benzimidazol-4-carboxamide
EA201171230A1 (en) SEROTONIN AND NOREPINEFRINE RETURN CAPTURE INHIBITOR
HK1140949A1 (en) Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-]
EA201070737A1 (en) THERAPEUTIC APPLICATION OF COMPOUNDS WITH AFFINITY TO SEROTONIN TRANSFER, SEROTONIN RECEPTORS AND NORADRENALINE TRANSFER
UA95801C2 (en) Crystalline forms of 4-[2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
EA201000611A1 (en) 4,4-DESIGNED PIPERIDINES
TH110866A (en) N-hydroxy salt -3- [4 - [[[2- (2-methyl-1H-indol-3-il) ethyl] amino] methyl] Phenyl] -2E-2-propinamide